Free 2 day AUS and US shipping for orders above $200 • Register for an account to receive 20% off

Melanotan II 10mg

Melanotan II 10mg

$44.00

Melanotan II 10mg is a synthetic peptide analogue of the alpha-melanocyte-stimulating hormone (α-MSH), designed to activate multiple melanocortin receptors (MCRs), including MC1, MC3, MC4, and MC5. As a cyclic peptide, Melanotan II exhibits enhanced stability and receptor binding affinity, making it valuable for melanocortin system research. Research has shown that: MC1 receptor activation plays a role in melanin synthesis and skin pigmentation pathways. MC4 receptor activation has been explored in studies related to neuroendocrine signaling and energy balance regulation. Melanotan II’s ability to act as a non-selective melanocortin receptor agonist makes it a useful model compound for studying melanocyte biology, pigmentation mechanisms, and melanocortin receptor pharmacology. Each vial of Melanotan II is HPLC-verified for >99% purity, ensuring consistency and reliability in laboratory research applications.

This material is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.

In Stock

Data Sheet

Molecular Formula C₅₀H₆₉N₁₅O₉
CAS Number 121062-08-6
Molar Mass 1024.18 g/mol
Amino Acid Sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2
PubChem CID 92432
Primary Research Area Energy Homeostasis
Body Mass Regulation
Appetite Suppression
Skin Pigmentation (Sunless Tanning)
Spontaneous Penile Erection & Sexual Stimulation
Purity >99%
Research Summary Description
Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study Summary: This pilot Phase 1 study aimed to evaluate the safety, tolerability, and melanogenic (tanning) effects of Melanotan II in healthy volunteers. While specific details on the tanning efficacy in this early pilot are limited in publicly available summaries, the study confirmed that Melanotan II could induce skin pigmentation. It also noted the occurrence of side effects, including nausea, flushing, and spontaneous erections in male subjects, which, while unintended, led to further research into its use for sexual dysfunction.

Citation:
Dorr, R. T., Lines, R., Levine, N., Brooks, C., Xiang, L., Hruby, V. J., & Hadley, M. E. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences, 58(20), 1777–1784.
Activation of the central melanocortin system chronically reduces body mass without the necessity of long-term caloric restriction Summary: This study demonstrated that chronic central administration of Melanotan II in rats led to a persistent reduction in body mass, even after food intake normalized following an initial transient anorexic response.

Citation: Lucas, M., Zhang, M., & Bi, S. (2015). Activation of the central melanocortin system chronically reduces body mass without the necessity of long-term caloric restriction. Physiology & Behavior, 152(Pt A), 1-8.
Melanotan II: a possible cause of renal infarction: review of the literature and case report Summary: A case report by Lund et al. (2020) described a renal infarction likely attributed to Melanotan II use, suggesting possible direct toxic effects on renal parenchyma and thrombotic influences. The peptide's ability to overstimulate the sympathetic nervous system, leading to vasoconstriction, was proposed as a mechanism for renal injury.

Citation: Lund, J., Thomsen, M., & Jensen, J. D. (2020). Melanotan II: a possible cause of renal infarction: review of the literature and case report. Clinical Kidney Journal, 13(2), 209-212.
Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. Summary: This early, small-scale human clinical trial (n=10) investigated Melanotan II's ability to induce erections in men with psychogenic erectile dysfunction. Participants received either Melanotan II (0.025 mg/kg subcutaneously) or a placebo. The study found that 8 out of 10 men treated with Melanotan II developed clinically apparent erections, with a significantly longer duration of rigidity compared to placebo. Transient side effects such as nausea, stretching, yawning, and decreased appetite were more frequently reported with Melanotan II.

Citation:
Wessells, H., Fuciarelli, K., Hansen, J., Hadley, M. E., Hruby, V. J., Dorr, R., & Levine, N. (1998). Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. The Journal of Urology, 160(2), 389–393.
Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies. Summary: This review article provides a broader perspective on melanocortin receptor agonists, including Melanotan II and its metabolite bremelanotide, for sexual dysfunction. It summarizes the central mechanism by which these peptides induce sexual arousal and erection, specifically through MC3 and MC4 receptor activation in the brain. It discusses the success of bremelanotide (derived from Melanotan II research) in later clinical trials for female sexual interest/arousal disorder, highlighting how the core mechanism identified with Melanotan II was refined into a more selective and tolerable drug for a specific indication.

Citation:
Pfaus, J. G., & Sadowski, B. (2014). Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies. Expert Opinion on Investigational Drugs, 23(11), 1477–1483.

Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study

Summary: This pilot Phase 1 study aimed to evaluate the safety, tolerability, and melanogenic (tanning) effects of Melanotan II in healthy volunteers. While specific details on the tanning efficacy in this early pilot are limited in publicly available summaries, the study confirmed that Melanotan II could induce skin pigmentation. It also noted the occurrence of side effects, including nausea, flushing, and spontaneous erections in male subjects, which, while unintended, led to further research into its use for sexual dysfunction.

Citation:
Dorr, R. T., Lines, R., Levine, N., Brooks, C., Xiang, L., Hruby, V. J., & Hadley, M. E. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences, 58(20), 1777–1784.

Activation of the central melanocortin system chronically reduces body mass without the necessity of long-term caloric restriction

Summary: This study demonstrated that chronic central administration of Melanotan II in rats led to a persistent reduction in body mass, even after food intake normalized following an initial transient anorexic response.

Citation: Lucas, M., Zhang, M., & Bi, S. (2015). Activation of the central melanocortin system chronically reduces body mass without the necessity of long-term caloric restriction. Physiology & Behavior, 152(Pt A), 1-8.

Melanotan II: a possible cause of renal infarction: review of the literature and case report

Summary: A case report by Lund et al. (2020) described a renal infarction likely attributed to Melanotan II use, suggesting possible direct toxic effects on renal parenchyma and thrombotic influences. The peptide's ability to overstimulate the sympathetic nervous system, leading to vasoconstriction, was proposed as a mechanism for renal injury.

Citation: Lund, J., Thomsen, M., & Jensen, J. D. (2020). Melanotan II: a possible cause of renal infarction: review of the literature and case report. Clinical Kidney Journal, 13(2), 209-212.

Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study.

Summary: This early, small-scale human clinical trial (n=10) investigated Melanotan II's ability to induce erections in men with psychogenic erectile dysfunction. Participants received either Melanotan II (0.025 mg/kg subcutaneously) or a placebo. The study found that 8 out of 10 men treated with Melanotan II developed clinically apparent erections, with a significantly longer duration of rigidity compared to placebo. Transient side effects such as nausea, stretching, yawning, and decreased appetite were more frequently reported with Melanotan II.

Citation:
Wessells, H., Fuciarelli, K., Hansen, J., Hadley, M. E., Hruby, V. J., Dorr, R., & Levine, N. (1998). Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. The Journal of Urology, 160(2), 389–393.

Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies.

Summary: This review article provides a broader perspective on melanocortin receptor agonists, including Melanotan II and its metabolite bremelanotide, for sexual dysfunction. It summarizes the central mechanism by which these peptides induce sexual arousal and erection, specifically through MC3 and MC4 receptor activation in the brain. It discusses the success of bremelanotide (derived from Melanotan II research) in later clinical trials for female sexual interest/arousal disorder, highlighting how the core mechanism identified with Melanotan II was refined into a more selective and tolerable drug for a specific indication.

Citation:
Pfaus, J. G., & Sadowski, B. (2014). Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies. Expert Opinion on Investigational Drugs, 23(11), 1477–1483.

All content and product details on this website are provided solely for informational and educational purposes.

View Cart (0 items)

Your cart is empty

Start Shopping
20% OFF